Risk of Geographic Atrophy in the Comparison of Age-related Macular Degeneration Treatments Trials
Top Cited Papers
Open Access
- 30 September 2013
- journal article
- research article
- Published by Elsevier BV in Ophthalmology
- Vol. 121 (1), 150-161
- https://doi.org/10.1016/j.ophtha.2013.08.015
Abstract
No abstract availableKeywords
Funding Information
- National Eye Institute (U10 EY017823, U10 EY017825, U10 EY017826, and U10 EY017828)
- National Institutes of Health
- Department of Health and Human Services
This publication has 30 references indexed in Scilit:
- Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trialThe Lancet, 2013
- Angiographic and Optical Coherence Tomographic Results of the MARINA Study of Ranibizumab in Neovascular Age-Related Macular DegenerationOphthalmology, 2007
- Ranibizumab versus Verteporfin for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Development of atrophy of the retinal pigment epithelium around disciform scarsBritish Journal of Ophthalmology, 2006
- Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular DegenerationOphthalmology, 2006
- Optical Coherence Tomography Findings After an Intravitreal Injection of Bevacizumab (Avastin®) for Neovascular Age-Related Macular DegenerationOphthalmic Surgery, Lasers and Imaging Retina, 2005
- Prevalence of Age-Related Macular Degeneration in the United StatesAmerican Journal of Ophthalmology, 2004
- The natural history of geographic atrophy, the advanced atrophic form of age-related macular degeneration.1999
- Histopathology of age-related macular degeneration.1999